In a 2023 study, Wang et al. [90] demonstrated that intraperitoneal injection of GLP-1 reduces the effect of tissue damage in mice dextran sodium sulphate (DSS)-induced colitis by inhibiting intestinal inflammation, maintaining the gut barrier and regulating the gut microbiota. This evidence concerns the gene GLP1R and colitis.